Literature DB >> 6190578

The relationship between immunization and circulating antigen-specific plaque-forming cells.

R J Falkoff, L P Zhu, A S Fauci.   

Abstract

The relationship between the appearance of cells producing antibody to tetanus toxoid (TT) in the circulation and the serum titers of anti-TT IgG following booster immunization has been studied. It was found that cells producing anti-TT antibody can be detected in the circulation in a hemolytic plaque assay using sheep red blood cells (SRBC) coated with TT by the chromic chloride method. In symmetric inhibition studies using cells from TT or keyhole limpet hemocyanin (KLH)-immune donors, the homologous antigen inhibited 100% of the PFC with no cross-inhibition. Thus, the plaque-forming cells (PFC) detected in this assay are specific for the immunizing antigen. No evidence of polyclonal B-cell activation in response to TT was found, as shown by a failure to detect any PFC against unmodified or KLH or human serum albumin-treated SRBC. In addition, the increase in total Ig-secreting cells observed in a staphylococcal protein A reverse hemolytic plaque assay was always accounted for by the number of anti-TT antibody-producing cells observed. The peak number of anti-TT antibody-producing cells varied between donors, but the kinetics of their appearance was highly reproducible--none before Day 5, peak numbers between Days 6 and 8, and a sharp decline with only rare anti-TT Ig-secreting cells in the circulation by Day 15 postimmunization. Anti-TT antibody-producing cells appeared in the circulation prior to any detectable increase in serum anti-TT antibody titers, and following the disappearance of PFC from the circulation, there was no further increase in serum IgG anti-TT levels. These observations demonstrate a marked specificity of B-cell activation on boosting with a recall antigen, and a parallelism between the appearance of activated B cells in the circulation and of IgG anti-TT synthesis by the subject as a whole.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6190578     DOI: 10.1016/0008-8749(83)90295-2

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  5 in total

1.  The kinetics and phenotype of the human B-cell response following immunization with a heptavalent pneumococcal-CRM conjugate vaccine.

Authors:  Elizabeth A Clutterbuck; Penny Salt; Sarah Oh; Arnaud Marchant; Peter Beverley; Andrew John Pollard
Journal:  Immunology       Date:  2006-11       Impact factor: 7.397

2.  Serotype-specific and age-dependent generation of pneumococcal polysaccharide-specific memory B-cell and antibody responses to immunization with a pneumococcal conjugate vaccine.

Authors:  Elizabeth A Clutterbuck; Sarah Oh; Mainga Hamaluba; Sharon Westcar; Peter C L Beverley; Andrew J Pollard
Journal:  Clin Vaccine Immunol       Date:  2007-11-21

3.  Appearance of IgG and IgA antibodies in human bile after tetanus toxoid immunization.

Authors:  P G Hansen; E J Hennessy; H Blake; R L Clancy; R Kamath; C Molenaar; A W Cripps; G D Jackson
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

4.  Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated.

Authors:  Hua-Xin Liao; Xi Chen; Supriya Munshaw; Ruijun Zhang; Dawn J Marshall; Nathan Vandergrift; John F Whitesides; Xiaozhi Lu; Jae-Sung Yu; Kwan-Ki Hwang; Feng Gao; Martin Markowitz; Sonya L Heath; Katharine J Bar; Paul A Goepfert; David C Montefiori; George C Shaw; S Munir Alam; David M Margolis; Thomas N Denny; Scott D Boyd; Eleanor Marshal; Michael Egholm; Birgitte B Simen; Bozena Hanczaruk; Andrew Z Fire; Gerald Voss; Garnett Kelsoe; Georgia D Tomaras; M Anthony Moody; Thomas B Kepler; Barton F Haynes
Journal:  J Exp Med       Date:  2011-10-10       Impact factor: 14.307

Review 5.  The human IgE repertoire.

Authors:  Elisabeth Gadermaier; Mattias Levin; Sabine Flicker; Mats Ohlin
Journal:  Int Arch Allergy Immunol       Date:  2013-11-30       Impact factor: 2.749

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.